AlphAIAlphAI — Financial news for AI agents
rttnews.comAUG 242 min read$SPRC

SciSparc Advances MDMA-PEA IP For PTSD As FDA Provides Psychedelic Drug Guidance

SciSparc (SPRC) and Clearmind (CMND) advanced their MDMA-PEA patent for PTSD treatment. The U.S. FDA issued psychedelic drug guidance, aiding their development. SPRC and CMND traded at $6.70 and $1.74 respectively, with slight premarket declines.

Original reporting
rttnews.com
Published Aug 24, 2026, 5:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 6:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$SPRC
Bullish
medium confidence
Mentioned
$SPRC · $CMND
Relevance
6/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$SPRCBullishLow
01

Why it matters

The guidance provides regulatory clarity, potentially accelerating clinical programs like SPRC's MDMA‑PEA.

02

Market read

New IP filing coupled with FDA guidance may modestly boost sentiment for both firms.

03

What to watch

Regulatory pathway still uncertain; competition in MDMA therapies is intensifying.

Relevance 6/10Novelty 7/10Timing: pre‑market today

Background

The FDA recently released guidance on psychedelic drug development, highlighting MDMA as a candidate therapy.

Company-level read

Ticker impact

$SPRCBullishMedium confidence
Context

SciSparc announced a new patent application for an MDMA‑PEA combination targeting PTSD, following recent FDA psychedelic guidance.

Expected impact

Modest upside if clinical data follow; no immediate price move expected.

Evidence & confidence

The patent filing is a fresh, material development but scale is limited to early‑stage biotech.

$CMNDBullishMedium confidence
Context

Clearmind Medicine is a partner in the SPRC MDMA‑PEA patent filing, expanding its psychedelic portfolio.

Expected impact

Slight upside potential pending further data.

Evidence & confidence

Partner involvement is new information but impact is indirect and modest.

Market effects

Sector

Adds to momentum in the psychedelic‑therapy sector.

Regional

U.S. biotech investors may show modest interest.

Global

Limited to niche biotech and psychedelic drug space.

Counterpoint

What could challenge this read

Patent filing may not translate to commercial value without clinical success.

Key entities

  • Company
    SciSparc Ltd.

    Biotech firm developing psychedelic therapies.

  • Company
    Clearmind Medicine Inc.

    Partner in the MDMA‑PEA collaboration.

Read at source← All news

Related articles

OCT 27
$CMNDLow

Clearmind completes patient recruitment for AUD trial segment

Clearmind Medicine (NASDAQ:CMND) completed patient recruitment for the first segment of Part B in its Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. The trial, involving 12 patients, will assess safety, tolerability, and early efficacy signals. Sites include Johns Hopkins, Yale, and Israeli medical centers. According to the company, this marks a significant step in evaluating CMND-100 in the target patient population.

investing.com1 min
OCT 27
$CMNDLow

Clearmind has recruited its first group of people with alcohol use disorder for a clinical trial.

Clearmind Medicine (Nasdaq: CMND) has completed patient recruitment for the first segment of Part B of its Phase I/IIa clinical trial for CMND-100, a potential treatment for alcohol use disorder (AUD). The trial, conducted at sites including Johns Hopkins and Yale, will assess safety, tolerability, and early efficacy signals in patients with moderate-to-severe AUD. According to the company, this marks a significant milestone in validating CMND-100's therapeutic potential.

stocktitan.net2 min
OCT 26
$SPRCMedAI 8/10

SPRC Stock Jumps As SciSparc Advances Tourette Trial And AI Pivot

SciSparc Ltd. (SPRC) stock surged 39.44% on October 26, 2026, driven by positive sentiment around its Tourette syndrome drug trial and AI initiatives. The company's subsidiary, NeuroThera Labs, advanced its drug candidate SCI-110 into a Phase IIb trial, while its AI division, CliniQuantum, demonstrated significant performance improvements. SPRC trades at a fraction of its book value, reflecting both skepticism and potential value if its pipeline or AI initiatives gain traction.

timothysykes.com2 min
OCT 22
$SPRCMedAI 8/10

Yale is one of three centers ready to receive a Tourette’s trial drug

SciSparc (Nasdaq: SPRC) announced that its subsidiary, NeuroThera Labs (TSXV: NTLX), has completed manufacturing and obtained regulatory approval for its Phase IIb clinical trial of SCI-110, a drug for Tourette Syndrome. The trial will be conducted at three sites, including Yale and Tel Aviv Sourasky Medical Center. SCI-110 combines dronabinol and PEA, aiming to address unmet treatment needs for TS. Patient enrollment is expected to begin soon, marking a significant milestone for NeuroThera.

stocktitan.net2 min
OCT 15
$SPRCMed

Why is Scisparc stock surging today?

Scisparc (SPRC) stock rose 37% in pre-market trading after announcing a strategic shift to AI-powered technologies, focusing on cybersecurity and fintech. The Tel Aviv-based firm, previously a clinical-stage pharmaceutical developer, plans to explore agentic AI opportunities but cautioned no guarantees. The surge contrasts with broader tech selloffs due to inflation fears. No analyst upgrades accompanied the news, with recent ratings being 'hold' and 'sell'.

investing.com1 min